A trial aiming to treat fronto-temporal dementia (FTD) due to granulin mutations utilised AAV-9-based progranulin gene replacement delivered via CT-guided ICM delivery in humans began in 2020 with a primary end point of safety (NCT04408625). The gene discussed is GRN; the disease is frontotemporal dementia.